Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

[Hypomethylation and multiple sclerosis, the susceptibility factor?].

Cara Terribas CJ, González Guijarro L.

Neurologia. 2002 Mar;17(3):132-5.

PMID:
11927101
2.

Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients.

Menor C, Fueyo J, Escribano O, Piña MJ, Redondo P, Cara C, Román ID, Fernández-Moreno MD, Guijarro LG.

Mult Scler. 2002 May;8(3):243-8.

PMID:
12120697
3.

Thiopurine methyltransferase activity in Spain: a study of 14,545 patients.

Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, Maté J, Guijarro LG.

Dig Dis Sci. 2007 May;52(5):1262-9. Epub 2007 Mar 2.

PMID:
17334911
4.

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.

Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.

Ther Drug Monit. 2007 Feb;29(1):1-5.

PMID:
17304143
5.

[Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites].

Alvarez Beltran M, Infante Pina D, Tormo Carnicé R, Segarra Cantón O, Redecillas Ferreiro S.

An Pediatr (Barc). 2009 Feb;70(2):126-31. doi: 10.1016/j.anpedi.2008.10.010. Epub 2009 Feb 3. Spanish.

6.

Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.

Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG.

Am J Gastroenterol. 2006 Dec;101(12):2769-76. Epub 2006 Oct 6.

PMID:
17026564
7.

Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.

Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.

Hepatogastroenterology. 2006 May-Jun;53(69):399-404.

PMID:
16795981
8.

A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.

Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.

Am J Gastroenterol. 2008 Dec;103(12):3115-22. doi: 10.1111/j.1572-0241.2008.01743.x. Erratum in: Am J Gastroenterol. 2009 Apr;104(4):1072. Biroulet, Laurent P [corrected to Peyrin-Biroulet, Laurent]. Retraction in: Am J Gastroenterol. 2009 Mar;104(3):801.

PMID:
19086961
9.

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.

Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, Meenan J, Yim A, Sanderson J.

Aliment Pharmacol Ther. 2002 Oct;16(10):1743-50.

10.

No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease.

Lindqvist M, Hindorf U, Almer S, Söderkvist P, Ström M, Hjortswang H, Peterson C.

Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1033-7.

PMID:
17065060
11.
12.

[Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity].

Gisbert JP, Gomollón F, Maté J, Pajares JM.

Rev Clin Esp. 2002 Oct;202(10):555-62. Review. Spanish. No abstract available.

PMID:
12361557
13.

Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.

Cao Q, Zhu Q, Shang Y, Gao M, Si J.

Digestion. 2009;79(1):58-63. doi: 10.1159/000205268. Epub 2009 Feb 28.

PMID:
19252404
14.

6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.

Roblin X, Serre-Debeauvais F, Phelip JM, Faucheron JL, Hardy G, Chartier A, Helluwaert F, Bessard G, Bonaz B.

Aliment Pharmacol Ther. 2005 Apr 1;21(7):829-39.

15.

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.

Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum M, Zanger UM, Kaskas BA.

Pharmacogenetics. 2002 Aug;12(6):429-36.

PMID:
12172211
16.

Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.

Schedel J, Gödde A, Schütz E, Bongartz TA, Lang B, Schölmerich J, Müller-Ladner U.

Ann N Y Acad Sci. 2006 Jun;1069:477-91.

PMID:
16855176
17.

Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.

Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y.

J Gastroenterol Hepatol. 2008 Sep;23(9):1373-7. doi: 10.1111/j.1440-1746.2008.05419.x. Epub 2008 Jul 23.

PMID:
18662197
18.
19.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
20.

[Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine].

Bessard G, Hardy G, Chartier A, Stanke-Labesque F.

Therapie. 2004 Jan-Feb;59(1):71-5. Review. French.

PMID:
15199672

Supplemental Content

Support Center